<DOC>
	<DOCNO>NCT00784940</DOCNO>
	<brief_summary>To assess quantify change bone mineral density ARIMIDEX ARIMIDEX plus NOLVADEX group compare NOLVADEX alone treatment group whilst receive trial therapy .</brief_summary>
	<brief_title>ATAC - Bone Density Sub-Protocol</brief_title>
	<detailed_description />
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Eligible entry main ATAC trial 1033IL/0029 Women define postmenopausal Patients histologically proven operable invasive breast cancer Who follow primary surgery good prognosis would ethically suitable remain untreated Excluded entry main ATAC trial ( 1033IL/0029 ) Patients receive hormone replacement therapy within previous 12 month prior randomisation Patients receive bisphosphonate therapy within previous 12 month prior randomisation Patients bone fracture within previous 6 month prior randomisation</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>